Wolfe Research Maintains Outperform on Flywire, Raises Price Target to $23
Wolfe Research analyst Darrin Peller maintains Flywire (NASDAQ:FLYW) with a Outperform and raises the price target from $22 to $23.
Read original at benzingaStocks · News reference
Wall Street analysts changed outlook on top names. For full changes, upgrades, downgrades and initiations, see analyst ratings page.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Wolfe Research analyst Darrin Peller maintains Flywire (NASDAQ:FLYW) with a Outperform and raises the price target from $22 to $23.
Read original at benzingaArcher Aviation and SpaceX represent two different aerospace plays with vastly different maturity levels. Archer is pre-commercial with $300K revenue and $618M losses, pursuing FAA certification for eVTOL aircraft. SpaceX generates $18.7B in revenue but reported a $5B net loss in FY2025 due to massive capital requirements. The article concludes SpaceX is the wiser long-term choice despite both companies' negative cash flows, citing SpaceX's established Starlink business and market support versus Archer's high valuation multiples and regulatory uncertainties.
Read original at the-motley-foolNvidia’s Unusual Move Please click here for an enlarged chart of NVIDIA Corp (NASDAQ:NVDA). Note the following: The chart shows that NVDA gapped up above the low band of Zone 1 (resistance). RSI on the
Read original at benzingaElon Musk, Sam Altman and Jensen Huang will attend a tech-focused G20 meeting in North Carolina next week.
Read original at benzingahttps://www.bloomberg.com/news/articles/2026-08-27/spacex-s-musk-david-sacks-to-join-altman-huang-at-g20-event
Read original at benzingaShattuck Labs (STTK) gained nearly 5% on Monday following positive analyst coverage from two firms. TD Cowen initiated a buy rating while Raymond James issued a strong buy with an $18 price target (more than double the $7.90 closing price). The optimism centers on the company's lead drug candidate SL-325, a first-in-class autoimmune and inflammatory disease treatment currently in Phase 2b clinical testing for inflammatory bowel disease, with analysts estimating a $20+ billion addressable market.
Read original at the-motley-fool